Evidence map›Paper›PMID 26331617›Full record

ArticlePloS one2015

Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis.

Agnieszka Latosinska, Konstantinos Vougas, Manousos Makridakis, Julie Klein, William Mullen, Mahmoud Abbas, Konstantinos Stravodimos, Ioannis Katafigiotis, Axel S Merseburger, Jerome Zoidakis and 3 more

Erratum issuedAbstract readComparative Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Agnieszka LatosinskaBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece; Charité-Universitätsmedizin Berlin, Berlin, Germany.
Konstantinos VougasBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Manousos MakridakisBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Julie KleinInstitut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institute of Cardiovascular and Metabolic Diseases, Toulouse, France; Université Toulouse III Paul-Sabatier, Toulouse, France.
William MullenBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Mahmoud AbbasDepartment of Pathology, Hannover Medical School, Hannover, Germany.
Konstantinos StravodimosDepartment of Urology, Medical School of Athens, Laikon Hospital, Athens, Greece.
Ioannis KatafigiotisDepartment of Urology, Medical School of Athens, Laikon Hospital, Athens, Greece.
Axel S MerseburgerDepartment of Urology, University of Lübeck, Lübeck, Germany.
Jerome ZoidakisBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Harald MischakBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Mosaiques Diagnostics GmbH, Hannover, Germany.
Antonia VlahouBiotechnology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Vera JankowskiRWTH-Aachen, Institute for Molecular Cardiovascular Research (IMCAR), Aachen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High resolution proteomics approaches have been successfully utilized for the comprehensive characterization of the cell proteome. However, in the case of quantitative proteomics an open question still remains, which quantification strategy is best suited for identification of biologically relevant changes, especially in clinical specimens. In this study, a thorough comparison of a label-free approach (intensity-based) and 8-plex iTRAQ was conducted as applied to the analysis of tumor tissue samples from non-muscle invasive and muscle-invasive bladder cancer. For the latter, two acquisition strategies were tested including analysis of unfractionated and fractioned iTRAQ-labeled peptides. To reduce variability, aliquots of the same protein extract were used as starting material, whereas to obtain representative results per method further sample processing and MS analysis were conducted according to routinely applied protocols. Considering only multiple-peptide identifications, LC-MS/MS analysis resulted in the identification of 910, 1092 and 332 proteins by label-free, fractionated and unfractionated iTRAQ, respectively. The label-free strategy provided higher protein sequence coverage compared to both iTRAQ experiments. Even though pre-fraction of the iTRAQ labeled peptides allowed for a higher number of identifications, this was not accompanied by a respective increase in the number of differentially expressed changes detected. Validity of the proteomics output related to protein identification and differential expression was determined by comparison to existing data in the field (Protein Atlas and published data on the disease). All methods predicted changes which to a large extent agreed with published data, with label-free providing a higher number of significant changes than iTRAQ. Conclusively, both label-free and iTRAQ (when combined to peptide fractionation) provide high proteome coverage and apparently valid predictions in terms of differential expression, nevertheless label-free provides higher sequence coverage and ultimately detects a higher number of differentially expressed proteins. The risk for receiving false associations still exists, particularly when analyzing highly heterogeneous biological samples, raising the need for the analysis of higher sample numbers and/or application of adjustment for multiple testing.

Indexed as

Chromatography, LiquidHumansNeoplasm ProteinsProteomicsTandem Mass SpectrometryUrinary Bladder NeoplasmsNeoplasm Proteins

Identifiers

PMID26331617
PMCPMC4557910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.